Systemic Chemotherapy for Pancreatic Cancer

Pancreas

Volumn 28, Issue 3, 2004, Pages 301-304

  Okusaka, Takuji ^a   Kosuge, Tomoo ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; S 1; Thymidylate synthase inhibitor 5 fluorouracil

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; THYMIDYLATE SYNTHASE INHIBITOR; UFT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; LEUKOPENIA; LOW DRUG DOSE; METASTASIS; MOLECULAR BIOLOGY; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; JAPAN; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 1842534971     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200404000-00017     Document Type: Article

References (24)

1. Matsuno S, Egawa S, Shibuya K, et al. Pancreatic cancer: current status of treatment and survival of 16071 patients diagnosed from 1981-1996, using the Japanese National Pancreatic Cancer Database. Int J Clin Oncol. 2000;5:153-157.
2. Okada S. Nonsurgical treatments of pancreatic cancer. Int J Clin Oncol. 1999;4:257-266.
3. Tajiri H, Yoshimori M, Okazaki N, et al. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology. 1991;48:18-21.
4. Ikeda M, Okada S, Ueno H, et al. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. Hepatogastroenterology. 2000;47:862-865.
5. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988;22:333-338.
6. Ueno H, Okada S, Okusaka T, et al. Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology. 2002;62:223-227.
7. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000;83:141-145.
8. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939-943.
9. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715-1720.
10. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-197.
11. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999;57:202-210.
12. Furuse K, Kawahara M, Hasegawa K, et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol. 2001;6:236-241.
13. Okada S, Okusaka T, Ueno H, et al. A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2002;21:171a.
14. Nose H, Okada S, Okusaka T, et al. 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study. Hepatogastroenterology. 1999;46:3244-3248.
15. Okusaka T, Okada S, Ishii H, et al. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 1996;26:215-220.
16. Tsuiji A, Morita S, Horimi T, et al. A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2002;21:158a.
17. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology. 1998;45:2020-2026.
18. Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer [in Japanese]. Gan To Kagaku Ryoho. 1994;21:1039-1046.
19. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016-1025.
20. Okada S, Sakata Y, Matsuno S, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer. 1999;80:438-443.
21. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
22. Taguchi T, Furuse K, Fukuoka M, et al. LY188011 phase I study [in Japanese]. Gan To Kagaku Ryoho. 1996;23:1101-1108.
23. Okada S, Ueno H, Okusaka T, et al. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2001;31:7-12.
24. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.